Safety, Tolerability, and Immunogenicity of a Recombinant Nonavalent Human Papillomavirus Vaccine (Escherichia coli) in Healthy Chinese Women Aged 18–45 Years: A Phase 1 Clinical TrialMingwei Wei, Yongjiang Liu, Huilong Yu et al.|Vaccines|2025Cited by 2
Immunogenicity and safety of an Escherichia coli-produced 9-valent human papillomavirus vaccine (types 6/11/16/18/31/33/45/52/58) in healthy Chinese women aged 20–45 years: a single-center, randomized, observer-blinded, positive controlled phase 2 clinical trialMingwei Wei, Jingxin Li, Hongyan Liu et al.|Frontiers in Immunology|2025Cited by 1